Boston, MA 09/29/2014 (wallstreetpr) – According to reports, Novartis AG (ADR)(NYSE:NVS)‘s drug Signifor LAR has got the recommendation of CHMP for the approval of EU. It can be used to cure patients that suffer from Acromegaly; a rare hormonal disorder.
Insights about Acromegaly:
As per the reports, it is an endocrine disorder, which is normally caused by insulin-like growth factor-1 and elevated growth hormone. There is hardly any well-acclaimed drug for the treatment of Acromegaly apart from Signifor LAR, which represents a complete new option for those patients who have acromegaly and lack any disease control. The Committee for Medicinal Products for Human Use has supported the usage of Signifor LAR, which is a major milestone for this drug. CHMP has supported its long-acting release formula to treat acromegaly in those patients for whom surgery is not an ideal option due to various health reasons. It has got a good response across the globe; therefore, Novartis AG (ADR)(NYSE:NVS) is looking forward to its registering process. Regulatory authorities are reviewing the drug and checking if it is compatible to be used by patients.
If Signifor LAR is approved in EU, then it can surely provide a solid treatment for acromegaly that causes a lot of deaths every year. It occurs in every one or two out of 10,000 people in EU due to unbalanced production of growth hormone and IGF-1[1], [4]. The major source of acromegaly is a noncancerous tumor in the pituitary gland. Those who are affected with this rare disease may experience various physical changes like excessive increment in the size of feet, hands, internal organs and face. It can also cause diabetes, heart attack and unexpected death. With the help of this drug, at least 45% of those patients will be directly benefitted whose growth hormone level remains controlled even after getting regular treatment from currently available SSAs (somatostatin analogue).
